FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Cancer patients take front line in early-stage trials

Tools

Frustrated by the long years of research needed to prove the effectiveness of a new cancer therapy, British officials have designated a network of 19 hospital units that will be allowed to administer early-stage experimental cancer drugs to terminal patients. John Gribben, a researcher at Bart's Hospital in London, told the Daily Telegraph that "We no longer have to wait to complete a study to see what happens to the cancer."

While likely to raise ethics concerns among some researchers using patients desperate to find a remedy for lethal cases of cancer, the new system could halve the 10 years that it currently takes to get an effective therapy onto the market. And Professor Gibben emphasizes that only patients with no hope of recovery will be placed in the pools of patients being assembled for these new studies. These studies will engage in dose-escalation tests, with small doses growing steadily larger as toxicity and efficacy are assessed.

- read the article in the Telegraph

Related Articles:
Abigail Alliance v. Von Eschenbach: A closer look. Editorial
FDA may boost experimental drug access. Report
Patients barred from obtaining experimental drugs. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Research Email Newsletter:
Be the first to comment

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.